Healthcare / BiotechnologyNasdaqGS
$11.49
-0.10 (-0.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-33.8M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
66/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$679M
P/E
5.7x
↓EV/EBITDA
6.7x
↓ROE
53.8%
↑Gross Margin
84.5%
↑Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-2.3%
FCF / Net income
-0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $106.5M · net income $83.2M · FCF $-2.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $106.5M | $106.5M | $23.6M | $27.5M | $10.2M | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 |
| Net Income | $83.2M | $83.2M | $-105.5M | $-46.0M | $-26.8M | $-8.6M | $-12.8M | $-24.5M | $-56.5M | $-43.4M | $-16.5M | $-54.7M | $-24.5M | $-5.2M |
| EBITDA | $98.7M | $98.7M | $-76.4M | $-43.5M | $-25.5M | $8.0M | $-5.3M | $-20.0M | $-55.6M | $-33.0M | $-37.3M | $-22.7M | $-16.4M | $-4.7M |
| EPS | 1.35 | 1.35 | -2.28 | -1.30 | -1.20 | -2.11 | -3.21 | — | — | — | — | — | — | — |
| Gross Margin | 84.5% | 84.5% | 68.6% | 92.1% | 97.8% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -4.0% | -4.0% | -368.5% | -180.6% | -245.1% | — | — | — | — | — | — | — | — | — |
| Net Margin | 78.2% | 78.2% | -446.9% | -167.7% | -263.5% | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.41 | 0.41 | 1.52 | 0.71 | 0.19 | — | -1.02 | -1.04 | -1.22 | -1.61 | — | — | — | — |
| Current Ratio | 4.89 | 4.89 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-2.4M | $-2.4M | $-69.7M | $-33.8M | $-18.8M | $10.3M | $-2.0M | $-23.8M | $-54.2M | $-33.3M | $-30.4M | $-20.4M | — | — |
| Returns | ||||||||||||||
| ROE | 53.8% | 53.8% | -266.0% | -74.4% | -35.6% | -8.4% | 19.2% | 32.9% | 84.8% | 75.4% | 88.3% | 540.1% | 50.4% | 21.5% |
| Valuation | ||||||||||||||
| P/E | 5.72 | 5.72 | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 6.67 | 6.67 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 4.25 | 4.25 | 10.02 | 3.40 | 2.10 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | 350.9% | 350.9% | -14.0% | 170.3% | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 159.2% | 159.2% | -75.4% | -8.3% | — | 34.3% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-8.9%
EPS terminal req.
$1.02
Spread vs growth
168.1%
5Y implied EPS CAGR
-1.8%
EPS terminal req.
$1.23
Spread vs growth
161.0%
10Y implied EPS CAGR
3.9%
EPS terminal req.
$1.99
Spread vs growth
155.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.28 → 1.35
Residual
+34.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.